Update: OXiGENE Earnings - Q2 Miss Challenges My Patience
- OXiGENE reported Q2 earnings yesterday, missing analyst estimates.
- In spite of this event, I reiterate my bull thesis on OXiGENE in light of the latest pipeline developments, which, in my opinion, counteract the negative earnings sentiment.
- While I anticipated important updates regarding EU requirements and scheduling of the full readout for Zybrestat/Avastin, I didn't anticipate the earnings miss. The latest earnings report corroborates this position.